Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4520767 | 1.00 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL4742177 | 0.93 | MBTD1 (0.42) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL4734690 | 0.93 | MBTD1 (0.42) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL4742181 | 0.91 | MBTD1 (0.41) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL4141018 | 0.81 | SLC18A3 (0.46) | IDO1TDO2MBTD1L3MBTL3SLC18A3 | |
| SCHEMBL2677605 | 0.78 | OPRL1 (0.59) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL632624 | 0.78 | OPRL1 (0.59) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL2675785 | 0.77 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL20844697 | 0.77 | OPRL1 (0.40) | OPRM1OPRD1OPRK1OPRL1IDO1 | |
| SCHEMBL2676517 | 0.77 | OPRM1 (0.55) | OPRM1OPRD1OPRK1OPRL1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297112-B1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2013-04-03 | — | — | EP | disclosed |
| US-8293917-B2 | Pyrazole compounds as CCR1 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2297112-A1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009137338-A1 | PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230521-A1 | Pyrazole Compounds As CCR1 Antagonists | CCR1, CCR3, CCR4 | OPRM1 1354/4885OPRD1 721/4885OPRK1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.